UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 61

of 'Approach to the patient following treatment for breast cancer'

61
TI
[18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer.
AU
Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW
SO
J Cancer Res Clin Oncol. 2003;129(3):147. Epub 2003 Mar 12.
 
AIM: To evaluate the role of [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients presenting with a suspicion of breast cancer relapse after primary treatment.
MATERIALS AND METHODS: Sixty consecutive female patients with clinical (n=35) or radiological (n=25) suspicion of breast cancer recurrence were evaluated by FDG-PET. Positive PET findings were further evaluated by histological examination or clinical and radiological follow-up. In 25 patients, the serum tumor marker (CA 15-3) status was compared to the PET results.
RESULTS: Disease relapse was proven in 40 patients. Additionally, in three patients a second cancer was diagnosed with (n=1), and without (n=2) concomitant disease relapse. PET missed local recurrence in three patients, and was false positive in another four. In patient-based analysis, the overall sensitivity, specificity, and accuracy were 89%, 84%, and 87%, and 100%, 97%, and 98% for locoregional recurrence and distant metastases, respectively. FDG-PET was more sensitive than the serum tumor marker CA 15-3 in detecting relapsed breast cancer.
CONCLUSION: FDG-PET is a valuable tool in the follow-up of patients with breast cancer.
AD
Division of Nuclear Medicine, Department of Medical Radiology, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
PMID